Journal profile · GENETICS & HEREDITY-NEUROSCIENCES
Molecular Autism
ISSN 2040-2392 · BioMed Central · ENGLAND · Founded 2010
Molecular Autism: CAS Zone 1 · Medicine (2025 upgraded edition, Top journal); impact factor 5.69; fully open access; APC about USD 3,990; median 151 days to acceptance (88 articles, last 24 months); 65 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Molecular Autism is published by BioMed Central and is in Zone 1 of Medicine in the CAS Journal Ranking (2025 upgraded edition, Top journal). By OpenAlex counts of its recent articles, its largest topics are Autism Spectrum Disorder Research, Genetics and Neurodevelopmental Disorders and Child Nutrition and Feeding Issues, together about 56.4% of its articles. (generated from OpenAlex topic counts and CAS ranking data)
Molecular Autism is a peer-reviewed, open access journal that publishes high-quality basic, translational and clinical research that has relevance to the etiology, pathobiology, or treatment of autism and related neurodevelopmental conditions. Research that includes integration across levels is encouraged. Molecular Autism publishes empirical studies, reviews, and brief communications. We encourage submissions from a range of fields including (but not restricted to) genetics, molecular neurobiology, neuropathology, neuroimaging, cognitive neuroscience, epidemiology, and biomarker discovery. Molecular Autism also publishes articles on screening, diagnosis and classification, including articles that consider subgrouping to refine our understanding of basic mechanisms. Intervention studies are also welcome, especially when considered with respect to revealing causal mechanisms. Although the primary focus is on conditions on the autism spectrum (including Asperger syndrome), the scope encompasses molecular research into related neurodevelopmental conditions such as specific language impairment, dyspraxia, and specific or general developmental delays; and into related medical syndromes such as fragile X syndrome, tuberous sclerosis, and Rett syndrome. Molecular Autism also considers articles with no molecular data but which, in the long-term, may close the gap from molecule to behavior in autism. The journal welcomes reports and reviews of good science that proceed from either end of this complex chain of events: from molecule upwards, or from behavior downwards. Reports and reviews can be basic and/or translational. Note that, because we rarely accept unsolicited reviews, we strongly encourage authors of potential reviews to make use of the presubmission inquiry system if they feel that an important topic has not been adequately reviewed and where, ideally, they are proposing a systematic review.
From the journal's Aims & Scope
Research area (LetPub): GENETICS & HEREDITY-NEUROSCIENCES
Editor-in-chief Evdokia AnagnostouPublisher website
Editorial board by country: none in mainland China; most named United States 28, United Kingdom 10, Canada 6, Italy 2, Japan 1 (54 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Autism Spectrum Disorder ResearchNeuroscience36.7%
- Genetics and Neurodevelopmental DisordersBiochemistry, Genetics and Molecular Biology13.8%
- Child Nutrition and Feeding IssuesMedicine5.9%
- Genomic variations and chromosomal abnormalitiesBiochemistry, Genetics and Molecular Biology4.6%
- Behavioral and Psychological StudiesPsychology4.4%
- Family and Disability Support ResearchPsychology4.4%
- Functional Brain Connectivity StudiesNeuroscience3.2%
- Attention Deficit Hyperactivity DisorderMedicine2.4%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Genetics & Heredity | Zone 1 |
| Minor | Neurosciences | Zone 1 |
Top journal: yesReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Genetics & Heredity | Zone 1 |
| Minor | Neurosciences | Zone 1 |
Top journal: yesReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Genetics & Heredity | Zone 1 |
| Minor | Neurosciences | Zone 1 |
Top journal: noReview journal: no
Database indexing
SCIEScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
MEDLINEEmbaseCASPublisher website
Other: Google Scholar, ProQuest, Dimensions, CNKI, Baidu, Naver, OCLC, Portico, CLOCKSS, Semantic Scholar
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 5.69LetPub ·
- Impact factor (publisher) 2025
- 5.7Publisher website ·
- 5-year impact factor (publisher) 2025
- 7Publisher website ·
- CiteScore 2026-06
- 8.6LetPub ·
- SJR 2026-06
- 1.79LetPub ·
- SNIP 2026-06
- 1.64LetPub ·
- h-index
- 44LetPub ·
- h-index
- 116OpenAlex ·
- i10-index
- 722OpenAlex ·
- 2-year mean citedness
- 5.66OpenAlex ·
- Self-citation rate
- 1.8%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 62LetPub ·
- Downloads per year (publisher) 2025
- 1,500,000Publisher website ·
Articles by year OpenAlex count · 905 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 46 | 46 | 27 |
| 2025 | 65 | 65 | 314 |
| 2024 | 54 | 54 | 593 |
| 2023 | 47 | 47 | 1,020 |
| 2022 | 53 | 53 | 1,724 |
| 2021 | 74 | 74 | 3,294 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
151 daysMedian, submission to acceptance · P25–P75 120 days – 199 days
- Acceptance to online
- median 19 days (88 articles)
- Submission to online
- median 171 days
- Sample
- 88 articles with submission and acceptance dates (125 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 17 weeksLetPub ·
- Submission to first decision
- 6 daysPublisher website ·
- Submission to publication (journal-reported)
- about 17 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | EUR 3,090 / USD 3,990 / GBP 2,690 | Yes | CC BY, CC BY-NC-ND | |
| OpenAlex | USD 3,990 / EUR 3,090 / GBP 2,690 | — | — | |
| LetPub | GBP 2,590 / USD 3,790 / EUR 2,990 | Yes | — | |
| Publisher website | Yes, amount not published | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Open calls for papers1, by deadline
Publisher websiteExcerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- BioMed Central
- Country or region
- ENGLAND
- Language
- English
- Founded
- 2010
- ISSN
- 2040-2392
- Official links
- Journal homepage ↗DOAJ
- Submission system ↗LetPub
- Author guidelines ↗LetPub
- Aims & Scope ↗LetPub
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗LetPub
- Editorial board ↗LetPub
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Molecular Autism
What CAS zone is Molecular Autism in?
In the 2025 upgraded edition of the CAS Journal Ranking, Molecular Autism is in Zone 1 of Medicine, and in Zone 1 of the minor category Genetics & Heredity / Neurosciences; it is a Top journal. In the 2026 Xinrui edition it is in Zone 1 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Molecular Autism?
The latest impact factor listed by LetPub is 5.69; CiteScore 8.6, h-index 116.
How long does peer review take at Molecular Autism?
Based on the dates recorded on 88 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 151 days (interquartile range 120–199 days); authors report an average review time of about 17 weeks. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Where are the editorial board members of Molecular Autism based?
Of the 54 board members whose country the journal's board page names, none are in mainland China; the countries named most often are United States (28), United Kingdom (10) and Canada (6). Counted from the institutions listed on the board page; for reference only.
Which databases index Molecular Autism?
According to LetPub and DOAJ records, Molecular Autism is indexed in SCIE, Scopus and DOAJ. The journal's website also lists MEDLINE, Embase and CAS; that list has not been checked against each database.
Is Molecular Autism open access, and what is the APC?
Molecular Autism is a fully open-access journal. APC about USD 3,990.
Sources and updates
The facts on this page come from LetPub, OpenAlex, DOAJ, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .